Previous 10 | Next 10 |
ACTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2021. The Company’s re...
ACTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, is pleased to welcome Andrew “Drew” M. Reynolds to the Psychemedics Board of Directors effective April 4 th , 202...
Psychemedics (NASDAQ:PMD) declares $0.05/share quarterly dividend. Forward yield 2.62% Payable Dec. 30; for shareholders of record Dec. 20; ex-div Dec. 17. See PMD Dividend Scorecard, Yield Chart, & Dividend Growth. Raymond C. Kubacki, Chairman and CEO, stated “Our Board of Directo...
ACTON, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced that it has declared a cash dividend of $0.05 per share to be paid on December 30 th , 2021 to shareholders of r...
In this week's newsletter, we look at a company in the middle of monetizing its major asset to see what is left after the deal closes. We also review a shipping company that has built a strong margin of safety. Lastly, we look at a drug testing company in the middle of a turnaroun...
29% YoY revenue growth in Q3, margins surge. EPS of $0.13 against loss per share of $0.20 in 3Q20. Worst seems to be over for the company, we expect dividends to eventually be reinstated as growth has resumed. 13x P/E, 7% FCF yield on “normal” 2023 estimates. ...
ACTON, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2021. The Company’s revenue for the quarter e...
Market-leading drug testing company, 30 years history, drug abuse increasing in the US. 13x P/E, 8% FCF yield on “normal” 2023 estimates. We expect resumption in dividends once financials improve. Worst seems to be over for the company and the base business is lo...
ACTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2021. The Company’s revenue for the quarter end...
ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year financial results for the period ended December 31, 2020. The Company's revenue ...
News, Short Squeeze, Breakout and More Instantly...
Psychemedics Corporation Company Name:
PMD Stock Symbol:
NASDAQ Market:
Psychemedics Corporation Website:
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a...
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024. The Company’s revenue for the quarter ended March 31,...
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the nega...